trending Market Intelligence /marketintelligence/en/news-insights/trending/af4q5sewlzszpvntgrpnrw2 content esgSubNav
In This List

Xeris Pharmaceuticals closes $98.3M IPO

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Xeris Pharmaceuticals closes $98.3M IPO

Xeris Pharmaceuticals Inc. closed its IPO to raise about $98.3 million in gross proceeds.

The Chicago-based specialty pharmaceutical company issued 6,555,000 common shares at $15 apiece. The total includes 859,800 shares bought by the underwriters after they exercised their option in full to buy the additional shares.

The company reported separately June 26 that two late-stage clinical trials showed that its ready-to-use glucagon rescue pen was safe and effective in treating emergency events for type 1 diabetes patients.

Xeris is listed on the Nasdaq Global Select Market under the symbol XERS.

Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities acted as joint book running managers for the offering.